Rodman & Renshaw Initiates Coverage on Ligand Pharmaceuticals (LGND) with a Market Outperform
Tweet Send to a Friend
Rodman & Renshaw initiates coverage on Ligand Pharmaceuticals (Nasdaq: LGND) with a Market Outperform. Price target $5.
Rodman ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Rodman ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE


